Despite significant advances, a clear consensus on the prognostic utility of secondary mutations beyond BRAF in thyroid cancer is lacking, leaving clinicians with limited guidance for integrating these markers into risk stratification frameworks. The gene discussed is BRAF; the disease is thyroid cancer.